Conservative treatments for feline fibroadenomatous changes of the mammary gland

Background: Fibroadenomatous changes (FAC) of the mammary gland in cats represents a benign, progesterone-associated fibroglandular proliferation of one or more mammary glands that may occur in intact female cats at the time of puberty, during pregnancy or pseudopregnancy, or in female and male cats...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gabriele Marino, Michela Pugliese, Fabiana Pecchia, Giuseppe Garufi, Vincenzo Lupo, Stefania Di Giorgio, Alessandra Sfacteria
Formato:	article
Lenguaje:	EN
Publicado:	Tripoli University 2021
Materias:	cat tumor aglepristone hypericum aloe Zoology QL1-991
Acceso en línea:	https://doaj.org/article/76aa6af2ec6a48c2bac0cb8f48ab1ad4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76aa6af2ec6a48c2bac0cb8f48ab1ad4
record_format	dspace
spelling	oai:doaj.org-article:76aa6af2ec6a48c2bac0cb8f48ab1ad42021-12-04T20:21:42ZConservative treatments for feline fibroadenomatous changes of the mammary gland10.5455/OVJ.2021.v11.i4.192226-44852218-6050https://doaj.org/article/76aa6af2ec6a48c2bac0cb8f48ab1ad42021-11-01T00:00:00Zhttps://www.openveterinaryjournal.com/OVJ-2021-07-133%20G.%20Marino%20et%20al.pdfhttps://doaj.org/toc/2226-4485https://doaj.org/toc/2218-6050Background: Fibroadenomatous changes (FAC) of the mammary gland in cats represents a benign, progesterone-associated fibroglandular proliferation of one or more mammary glands that may occur in intact female cats at the time of puberty, during pregnancy or pseudopregnancy, or in female and male cats of any age under progestin treatment. Nowadays, the elective treatment of FAC is based on the progesterone antagonist aglepristone. This study aimed to report the treatment of FAC with a combination of drugs designed to preserve mammary gland integrity, even in pregnant cats. Case Description: Eight sexually intact female cats with fibroadenomatous changes showed mammary glands that were symmetrically enlarged and inflamed in all cases, and the skin was ulcerated in six cats. Four cats were on days 25-32 of pregnancy at presentation. Non-pregnant cats were treated with aglepristone and with a dietary supplement containing maltodextrin and bromelain. The mammary glands were massaged daily with an Aloe vera emollient gel. If the gland was inflamed or ulcerated, broad-spectrum antimicrobial and anti-inflammatory treatments were given, and the ulcers were treated topically with a hypericum and neem-based cream. Two of the four pregnant cats were treated with the same therapeutic schedule plus cloprostenol to facilitate uterine emptying. Two pregnant cats underwent the same protocol except for aglepristone, which was not administered to safeguard the litter and see if the adjuvant therapy worked independently. At term, they delivered four and three kittens respectively, that were normally nursed and weaned after 40 days. In all the studied cases, the mammary gland reduced in size 2-3 weeks after the start of the treatment and completely remitted after 4-5 weeks. Conclusion: This case series encourages adjuvant therapy in the course of FAC to preserve mammary gland integrity and functionality. Exploiting the natural decline of progesterone at the end of pregnancy (or pseudopregnancy), the therapy may also be used without aglepristone, when its use has other limitations.Gabriele MarinoMichela PuglieseFabiana PecchiaGiuseppe GarufiVincenzo LupoStefania Di GiorgioAlessandra SfacteriaTripoli UniversityarticlecattumoraglepristonehypericumaloeZoologyQL1-991ENOpen Veterinary Journal, Vol 11, Iss 4, Pp 680-685 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cat tumor aglepristone hypericum aloe Zoology QL1-991
spellingShingle	cat tumor aglepristone hypericum aloe Zoology QL1-991 Gabriele Marino Michela Pugliese Fabiana Pecchia Giuseppe Garufi Vincenzo Lupo Stefania Di Giorgio Alessandra Sfacteria Conservative treatments for feline fibroadenomatous changes of the mammary gland
description	Background: Fibroadenomatous changes (FAC) of the mammary gland in cats represents a benign, progesterone-associated fibroglandular proliferation of one or more mammary glands that may occur in intact female cats at the time of puberty, during pregnancy or pseudopregnancy, or in female and male cats of any age under progestin treatment. Nowadays, the elective treatment of FAC is based on the progesterone antagonist aglepristone. This study aimed to report the treatment of FAC with a combination of drugs designed to preserve mammary gland integrity, even in pregnant cats. Case Description: Eight sexually intact female cats with fibroadenomatous changes showed mammary glands that were symmetrically enlarged and inflamed in all cases, and the skin was ulcerated in six cats. Four cats were on days 25-32 of pregnancy at presentation. Non-pregnant cats were treated with aglepristone and with a dietary supplement containing maltodextrin and bromelain. The mammary glands were massaged daily with an Aloe vera emollient gel. If the gland was inflamed or ulcerated, broad-spectrum antimicrobial and anti-inflammatory treatments were given, and the ulcers were treated topically with a hypericum and neem-based cream. Two of the four pregnant cats were treated with the same therapeutic schedule plus cloprostenol to facilitate uterine emptying. Two pregnant cats underwent the same protocol except for aglepristone, which was not administered to safeguard the litter and see if the adjuvant therapy worked independently. At term, they delivered four and three kittens respectively, that were normally nursed and weaned after 40 days. In all the studied cases, the mammary gland reduced in size 2-3 weeks after the start of the treatment and completely remitted after 4-5 weeks. Conclusion: This case series encourages adjuvant therapy in the course of FAC to preserve mammary gland integrity and functionality. Exploiting the natural decline of progesterone at the end of pregnancy (or pseudopregnancy), the therapy may also be used without aglepristone, when its use has other limitations.
format	article
author	Gabriele Marino Michela Pugliese Fabiana Pecchia Giuseppe Garufi Vincenzo Lupo Stefania Di Giorgio Alessandra Sfacteria
author_facet	Gabriele Marino Michela Pugliese Fabiana Pecchia Giuseppe Garufi Vincenzo Lupo Stefania Di Giorgio Alessandra Sfacteria
author_sort	Gabriele Marino
title	Conservative treatments for feline fibroadenomatous changes of the mammary gland
title_short	Conservative treatments for feline fibroadenomatous changes of the mammary gland
title_full	Conservative treatments for feline fibroadenomatous changes of the mammary gland
title_fullStr	Conservative treatments for feline fibroadenomatous changes of the mammary gland
title_full_unstemmed	Conservative treatments for feline fibroadenomatous changes of the mammary gland
title_sort	conservative treatments for feline fibroadenomatous changes of the mammary gland
publisher	Tripoli University
publishDate	2021
url	https://doaj.org/article/76aa6af2ec6a48c2bac0cb8f48ab1ad4
work_keys_str_mv	AT gabrielemarino conservativetreatmentsforfelinefibroadenomatouschangesofthemammarygland AT michelapugliese conservativetreatmentsforfelinefibroadenomatouschangesofthemammarygland AT fabianapecchia conservativetreatmentsforfelinefibroadenomatouschangesofthemammarygland AT giuseppegarufi conservativetreatmentsforfelinefibroadenomatouschangesofthemammarygland AT vincenzolupo conservativetreatmentsforfelinefibroadenomatouschangesofthemammarygland AT stefaniadigiorgio conservativetreatmentsforfelinefibroadenomatouschangesofthemammarygland AT alessandrasfacteria conservativetreatmentsforfelinefibroadenomatouschangesofthemammarygland
_version_	1718372681176317952

Conservative treatments for feline fibroadenomatous changes of the mammary gland

Ejemplares similares